SETD7 methyltransferase is a key druggable target for effective cardioprotection from myocardial ischaemic injury

Cardiovasc Res. 2023 Jan 18;118(17):3269-3271. doi: 10.1093/cvr/cvac148.

Authors

Daniele Torella¹, Nadia Salerno², Eleonora Cianflone²

Affiliations

¹ Department of Experimental and Clinical Medicine, Magna Graecia University, Campus S. Venuta, Viale Europa, 88100 Catanzaro, Italy.
² Department of Medical and Surgical Sciences, Magna Graecia University, 88100 Catanzaro, Italy.

PMID: 36056836
DOI: 10.1093/cvr/cvac148

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Heart Injuries*
Histone-Lysine N-Methyltransferase / genetics
Histone-Lysine N-Methyltransferase / metabolism
Humans
Ischemia
Methylation
Methyltransferases*
Protein Processing, Post-Translational
Signal Transduction

Substances

Methyltransferases
SETD7 protein, human
Histone-Lysine N-Methyltransferase